Introduction
Prostate cancer (PC) is the most common cancer in men and the third most frequent cause of cancer-related death in men worldwide (1) . After primary treatment, in approximately 30-40% of patients biochemical recurrence (BCR) occurs. After potential salvage treatment options patients are usually treated with androgen-deprivation therapy (ADT). Typically after 2-8 years of ADT, PSA begins to rise again indicating metastatic castration resistant prostate cancer (mCRPC), the lethal form of the disease.
In the primary setting, detection of extra-prostatic spread is crucial for further treatment planning as well as prognosis. However, cross-sectional imaging and bone scintigraphy, as recommended in many guidelines, have shown limitations in detecting sites of nodal or bone involvement in pre-operative patients (2) (3) (4) . Further, in patients with high suspicion of PC, multiparametric magnetic resonance imaging (mpMRI) helps to rule out clinically significant disease and to guide targeted biopsy (5) , although mpMRI can miss aggressive PC lesions (6) . In the BCR accurate restaging is crucial as local vs. systemic disease substantially influences further treatment management. Accurate diagnosis of the site(s) and extent of disease can be used in tailoring potential salvage treatments; however, standard of care imaging also has sensitivity and specificity limitations in this regard.
In contrast, positron emission tomography/computed tomography (PET/CT) combining functional and morphological information is increasingly being used within the last decade for PC imaging. 18 F-FDG is the most widely used radiotracer in oncologic PET/CT imaging; however, only a minority of PC (i. e. only aggressive, poorly differentiated or undifferentiated PC) show a high glycolytic rate, limiting the use of 18 F-FDG PET (7, 8) . In Europe, radiolabelled choline derivatives ( 18 F-fluorocholine or 11 C-choline) were amongst the most commonly used PET tracers for PC imaging. They were most frequently used for restaging of PC and primary staging in selected cases (e.g. high risk PC). Detection and localization of primary PC is limited by by on October 30, 2017 . For personal use only. jnm.snmjournals.org Downloaded from nonspecific uptake in benign intraprostatic pathologies (9) . Recent metaanalyses reported a high specificity of 95%, but a poor sensitivity of 49% in primary nodal staging (10) . Detection rates are positively associated with PSA-level, but low (<50%) in patients with early BCR (i.e. PSA-value <2 ng/ml) (11) . Other PET radiopharmaceuticals such as 11 C-Acetate have been investigated or even FDA approved, such as 18 F-FACBC in parts demonstrating superiority compared to choline derivatives (12) (13) (14) (15) .
Given the limitations with the most widely investigated PET tracers, targeting the prostatespecific membrane antigen (PSMA) with molecular imaging agents has recently been increasingly investigated. PSMA is a transmembrane protein that is highly overexpressed (100-1000 fold) on almost all PC tumors (16) (17) (18) (19) . Only 5-10% of primary PC lesions have been shown to be PSMA-negative (20, 21) . PSMA expression levels increase with higher tumor stage and grade (16, 18, 22) . Presently, the only FDA approved PSMA-agent is a radiolabelled anti-PSMA antibody (ProstaScint, capromab pendetide; EUSA Pharma, Langhorne, PA); however, this targets an intracellular epitope of PSMA (7E11) (19) which cannot be accessed in viable tumor cells and limits diagnostic performance (23) .
In contrast, small molecule PSMA ligands bind to the active site in the extracellular domain of PSMA and are internalized and endosomally recycled, leading to enhanced tumor uptake and retention and high image quality (24) (25) (26) (27) . The most widely used 68 Ga-labelled PSMA-ligands for PET-imaging are 68 Ga-PSMA-11 (syn. 68 Ga-PSMA-HBED-CC) and the theranostic agents 68 Ga-PSMA-617 and 68 Ga-PSMA-I&T (28, 29) . 18 F-labelled agents include 18 F-DCFBC (30,31), 18 FDCFPyL (32) and 18 F-PSMA 1007 (33) . They exploit the average lower positron range reducing blurring effects, longer half-life and the potential of centralized production and distribution of 18 F compared to 68 Ga. An (also tabular) overview of the most common PSMA ligands in clinical use was recently published (34) . are used for local and nodal recurrence, stereotactic RT for oligometastatic disease or systemic treatment in disseminated disease. Therefore, accurate restaging is crucial in recurrent PC patients. Currently, imaging of BCR is the most clinically accepted and validated indication for PSMA ligand PET/CT. As a prospective head-to-head comparison of 68 Ga-PSMA ligands and choline derivatives is missing, several, mainly retrospective, studies investigating BCR patients showed a higher diagnostic efficacy for PSMA ligand to choline derivatives (35-37). SUV max and tumor-to-background ratios were superior for 68 Ga-PSMA-11 compared to 18 F-fluorocholine (35), and 68 Ga-PSMA-11 showed a higher detection rate than 11 C-choline for lymph nodes as well as bone metastases (37). Positive findings exclusively detected by 18 F-fluorocholine PET/CT were rare (36). Three large retrospective studies (including 319 patients, 248 and 1,007 patients, respectively) reported detection rates for 68 Ga-PSMA-11 PET/CT in BCR of 88% and almost 90% (38-40). In patients after curative treatment with a very low PSA level of <0.5 ng/mL the reported detection rate of PSMA ligand PET/CT ranged from 50 to 58% in different studies (36, (38) (39) (40) 18 F-DCFPyL PET/CT were both superior compared to standard of care imaging for detecting suspicious lesions (32, 43) . In a head-to-head comparison in 14 patients with recurrent PC, staging with 18 F-DCFPyL PET/CT was equivalent to 68 Ga-PSMA-11 (44). A follow-up study from the same group using PSAadjusted parallel biochemically recurrent PC patient cohorts (including a total of 191 patients)
found that 18 F-DCFPyL was non-inferior to 68 Ga-PSMA-11 (45) and suggested an improved sensitivity of the 18 F-labelled radiotracer in the PSA range of 0.5-3.5 ng/mL (with the caveat that different injected doses and acquisition parameters were utilized for the two PSMA-targeted agents). Further in-depth clinical studies with standardized acquisition protocols and histological validation are needed to establish the comparative performance of these two radiotracers.
Primary Staging
In high-risk PC patients diagnosis of local extent and extra-prostatic spread, i.e. sites and extent of nodal and distant metastases, is crucial influencing further treatment planning (standard nodal dissection vs. extended dissection; change of primary RT field). Growing evidence underscores the role of PSMA ligand PET/CT imaging in primary PC, especially for N-/M-staging in a highby on October 30, 2017. For personal use only. jnm.snmjournals.org Downloaded from risk population. In detecting sites of nodal or bone involvement in pre-operative patients crosssectional imaging has shown a limited pooled sensitivity and specificity of 42% and 82% for CT and 39% and 82% for MRI, respectively (3), as up to 80% of lymph node metastases in PC are harbored in normal sized lymph nodes (2) . Several studies showed a clear superiority of PSMA ligand PET/CT compared to standard of care imaging (CT, MRI or bone scan) (21, (46) (47) (48) (49) . For example, in a retrospective analysis of 130 patients with primary intermediate to high-risk PC using template based pelvic histopathology as reference, 68 Ga-PSMA-11 PET performed significantly better than morphological imaging for N-staging both on a patient and a template basis (p=0.002 and <0.001, respectively). On template based analysis the sensitivity, specificity and accuracy were 68.3%, 99.1% and 95.2% for 68 Ga-PSMA-11 PET and 27 .3%, 97.1% and 87.6% for morphological imaging, respectively (21) . Similar results on the diagnostic efficacy of PSMA ligand PET for the detection of nodal metastases were obtained in other studies (47,49).
For bone metastases, Pyka et al. demonstrated that 68 Ga-PSMA-11 PET significantly outperformed bone scan due both to its high sensitivity and high specificity on a patient and region basis (p=0.006 and p<0.0001, respectively). As a histologic gold standard is not feasible in most cases for bone lesions a best valuable comparator was defined based in this study on a consensus review of all available current and follow-up images (including bone scan/SPECT,
PET, CT, MR) and clinical data (48).
In regards to intraprostatic tumor localization by 68 Ga-PSMA-11 PET/CT, imaging findings were correlated with histopathology using segment or voxel-based approaches in several studies (50-52). These studies demonstrated relatively similar results with a significantly higher 68 Ga-PSMA-11 uptake in positive segments compared to negative segments (SUV max 11.8 vs. 4.9 and 11.0 vs. 2.7, respectively, p < 0.001 each) (50,51). Results from combining 68 Ga-PSMA-11 and mpMRI on 53 preoperative intermediate/high risk patients indicated a potential for targeting biopsies. Hybrid 68 Ga-PSMA-11 PET/MRI significantly outperformed by on October 30, 2017. For personal use only. jnm.snmjournals.org Downloaded from mpMRI and 68 Ga-PSMA-11 PET in sensitivity and specificity for tumor localization on a sextant basis (76% and 97% for hybrid 68 Ga-PSMA-11 PET/MRI, 58% and 82% for mpMRI and 64%
and 94% for 68 Ga-PSMA PET, respectively) (53).
Using 18 F-labelled compounds in a first cohort of 13 patients, sensitivity of MRI in the detection of primary PC was superior to 18 F-DCFBC PET/CT; however, 18 F-DCFBC PET/CT demonstrated a higher specificity for clinically significant disease (31) . The relatively low sensitivity of 18 F-DCFBC in this context was likely at least partially attributable to its high blood pool activity and low tumor-to-background ratios in relation to other small molecule PSMAtargeted ligands, limitations potentially addressed by newer 18 F-labeled agents such as 18 FDCFPyL and 18 F-PSMA 1007. A first retrospective study using 18 F-PSMA 1007 imply its high diagnostic potential by correctly detecting 18 out of 19 histopathologically validated lymph node metastases in 8 patients with primary PC (33).
Advanced Disease
Typically after 2-8 years of ADT the rise of PSA heralds the onset of mCRPC which is the lethal form of the disease and requires further systemic treatment (second ADT and taxan based chemotherapy). The role of choline PET/CT in monitoring of systemic treatment in mCRPC has been investigated in previously published studies and is still under debate (54,55). Sclerotic bone metastases are not regarded as "target lesions" using RECIST 1.1 and bone scintigraphy suffers from the well-known "flare phenomenon". As preclinical data show that changes in PSMA-expression can indicate therapeutic success of taxane-based therapy (56), PSMA ligand PET/CT might overcome many of the limitations of standard of care imaging. However, ADT might represent a potential confounder due to temporal PSMA upregulation after initiation, followed by downregulation and finally gross overexpression in androgen resistant tumors as has been found in preliminary studies (57-60). 
Impact on Treatment Planning
Treatment management of PC is highly associated with the site(s) and extent of disease 
Patient Preparation and PSMA ligand PET/CT Image Acquisition

Patient Preparation
Patients should be well hydrated before the study and during uptake time (e.g. 500 mL of water orally during a 2 h period prior to acquisition). To reduce artifacts due to high tracer activity in the urinary system (potentially resulting in "halo artefacts" as well as false positive findings) it is beneficial to co-inject furosemide at the time of tracer injection and to empty the bladder immediately prior to image acquisition (79). Rectal filling with a negative contrast agent (100-150 mL) is optional to improve anatomical delineation of the rectum and differentiation of e.g. lymph nodes and seminal vesicles from adjacent structures. 
PET/CT Acquisition
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Practical Issues
Image Display and Reading
Hybrid PET/CT image review is recommended on a dedicated post-processing workstation allowing parallel visualization of PET-, CT-, and PET/CT fused images in the axial, coronal, and sagittal planes as well as maximum intensity projections (3D cine mode). PET and CT should be linked at the same table position to help localize PET-positive findings. For PET interpretation, by on October 30, 2017. For personal use only. jnm.snmjournals.org Downloaded from both uncorrected and attenuation-corrected images need to be assessed to identify artifacts (e.g. from contrast agents, metal implants, patient motion). Further, dynamic variation of SUVtreshold by changing display windowing is necessary to adjust e.g. the uptake of PSMA-ligands in/or adjacent to organs with high background such as the kidneys, ureter or the urinary bladder.
Otherwise findings such as local recurrence near the urinary bladder might be missed. Semiquantitative information of suspicious lesions (SUV mean/max ) can be derived on all slices of the attenuation corrected PET using a 3D volume-of-interest. Notably, currently no SUV-thresholds have been stringently defined that reliably aid in differentiation between benign and malignant lesions. Diagnostic contrast-enhanced CT should be evaluated separately according to established radiological criteria on a dedicated post-processing workstation.
Physiological PSMA Uptake and Variants
All low-molecular-weight PSMA ligands for PET-imaging demonstrate typical physiologic PSMA ligand uptake in the lacrimal glands, parotid glands, submandibular glands, liver, spleen, small intestine, kidneys, and colon (for an image example see Figure 3) . Notably, PSMA ligand uptake in the salivary gland is not finally proven to be related to PSMA-expression in the tissue. In addition, PSMA is synonymous with N-acetyl-L-aspartyl-L-glutamate peptidase I which is an enzyme expressed in human brain tissue and has a role of regulating Glutamate concentration.
All 68 Ga-and 18 F-labelled PSMA ligands are excreted via the kidneys with subsequent high radiotracer uptake in kidneys and urinary collection (16) . Limited preliminary data indicate that 18 F-PSMA 1007 might have reduced urinary clearance within the first two hours post injection potentially allowing for improved assessment of the prostate within this time window (33).
Pathologic PSMA uptake related to PC and metastases
The excellent specificity of PSMA ligands especially for lymph node metastases was demonstrated in several studies (21, 39, 46, (83) (84) (85) . Therefore, any focal uptake of the PSMAligand higher than the surrounding background in morphologically visible lesions and not associated with physiological uptake should be considered suspicious.
The pathologic uptake should be reported as low, moderate or intense by comparison to the background uptake e.g. compared to liver or spleen as recently described (86). Besides local involvement (primary tumor vs. local recurrence), the typical metastatic pattern is primarily the regional pelvic lymph nodes. This is often followed by distant lymph nodes (above the aortic bifurcation) and bone metastases. In advanced disease, PC can even spread to the liver, lungs or other visceral organs.
Limitations and Pitfalls in Clinical Interpretation
It is also well known that the neovasculature of many solid tumors can also expresses PSMA (22) . Accordingly, there is increasing evidence that PSMA ligand uptake is not exclusively specific for PC. A large number of case series and reports describe increased PET-signal in benign lesions (e.g. neurogenic tissue, Paget´s disease, thyroid adenoma, granulomatous disease, adrenal adenoma, etc.) as well as in malignant pathologies (e.g. renal cell carcinoma, lung cancer, glioblastoma, hepatocellular carcinoma, and thyroid cancer) (87-95). Table 1S (supplemental data) summarizes the current evidence in the literature. As many of these potential pitfalls can be solved in clinical context or by adding further imaging, increased PSMA ligand uptake in ganglia is the most common pitfall (for an image example see Figure 4 ). Their sites (especially sacral and coeliac) are near the typical locations of lymph node metastases.
Thus, knowledge of the CT-characteristics (e.g. size, shape, and specific location) is crucial for reliable differentiation. In a recent investigation, at least one coeliac ganglion with increased PSMA ligand uptake mimicking retroperitoneal lymph node disease was found in 89% of patients by on October 30, 2017. For personal use only. jnm.snmjournals.org Downloaded from undergoing 68 Ga-PSMA-11 PET/CT examinations (96) . Another important limitation is the absent PSMA-overexpression in the primary tumor and/or its metastases in up to 10% of patients with primary PC or (as mentioned above) decreased PSMA-expression in advanced disease (21) .
Side-by-side interpretation of the diagnostic CT scan as part of the PSMA ligand PET/CT examination is important. An example of a patient with a PSMA-positive rib fracture can be seen in Figure 5 . 
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